TY - JOUR
T1 - Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
AU - Spampinato, Sofia
AU - Tanderup, Kari
AU - Lindegaard, Jacob C.
AU - Schmid, Maximilian P.
AU - Sturdza, Alina
AU - Segedin, Barbara
AU - Jürgenliemk-Schulz, Ina M.
AU - de Leeuw, Astrid
AU - Bruheim, Kjersti
AU - Mahantshetty, Umesh
AU - Chargari, Cyrus
AU - Rai, Bhavana
AU - Cooper, Rachel
AU - van der Steen-Banasik, Elzbieta
AU - Sundset, Marit
AU - Wiebe, Ericka
AU - Villafranca, Elena
AU - van Limbergen, Erik
AU - Pieters, Bradley R.
AU - Tee Tan, Li
AU - Lutgens, Ludy C. H. W.
AU - Hoskin, Peter
AU - Smet, Stéphanie
AU - Pötter, Richard
AU - Nout, Remi
AU - Chopra, Supriya
AU - Kirchheiner, Kathrin
N1 - Funding Information:
The EMBRACE study was supported by Elekta AB and Varian Medical System through unrestricted research grants and study sponsoring through the Medical University of Vienna. The work of this manuscript was supported via grants from the Danish Cancer Society (R269-A15548).
Publisher Copyright:
© 2023 The Authors
PY - 2023/4/1
Y1 - 2023/4/1
N2 - Purpose: To quantify the association of persistent morbidity with different aspects of quality of life (QOL) in locally advanced cervical cancer (LACC) survivors. Material and methods: Longitudinal outcome from the EMBRACE-I study was evaluated. Patient-reported symptoms and QOL were prospectively scored (EORTC-C30/CX24) at baseline and regular follow-ups. Physician-assessed symptoms were also reported (CTCAEv.3). Persistent symptoms were defined if present in at least half of the follow-ups. QOL items were linearly transformed into a continuous scale. Linear mixed-effects models (LMM) were applied to evaluate and quantify the association of persistent symptoms with QOL. Overall QOL deterioration was evaluated by calculating the integral difference in QOL over time obtained with LMM for patients without and with persistent symptoms. Results: Out of 1416 patients enrolled, 741 with baseline and ≥ 3 late follow-ups were analyzed (median 59 months). Proportions of persistent EORTC symptoms ranged from 21.8 % to 64.9 % (bowel control and tiredness). For CTCAE the range was 11.3–28.6 % (limb edema and fatigue). Presence of any persistent symptom was associated with QOL, although with varying magnitude. Role functioning and Global health/QOL were the most impaired aspects. Fatigue and pain showed large differences, with reductions of around 20 % for most of the QOL aspects. Among organ-related symptoms, abdominal cramps showed the largest effect. Conclusion: Persistent symptoms are associated with QOL reductions in LACC survivors. Organ-related symptoms showed smaller differences than general symptoms such as fatigue and pain. In addition to optimizing treatment to minimize organ-related morbidity, effort should be directed towards a more comprehensive and targeted morbidity management.
AB - Purpose: To quantify the association of persistent morbidity with different aspects of quality of life (QOL) in locally advanced cervical cancer (LACC) survivors. Material and methods: Longitudinal outcome from the EMBRACE-I study was evaluated. Patient-reported symptoms and QOL were prospectively scored (EORTC-C30/CX24) at baseline and regular follow-ups. Physician-assessed symptoms were also reported (CTCAEv.3). Persistent symptoms were defined if present in at least half of the follow-ups. QOL items were linearly transformed into a continuous scale. Linear mixed-effects models (LMM) were applied to evaluate and quantify the association of persistent symptoms with QOL. Overall QOL deterioration was evaluated by calculating the integral difference in QOL over time obtained with LMM for patients without and with persistent symptoms. Results: Out of 1416 patients enrolled, 741 with baseline and ≥ 3 late follow-ups were analyzed (median 59 months). Proportions of persistent EORTC symptoms ranged from 21.8 % to 64.9 % (bowel control and tiredness). For CTCAE the range was 11.3–28.6 % (limb edema and fatigue). Presence of any persistent symptom was associated with QOL, although with varying magnitude. Role functioning and Global health/QOL were the most impaired aspects. Fatigue and pain showed large differences, with reductions of around 20 % for most of the QOL aspects. Among organ-related symptoms, abdominal cramps showed the largest effect. Conclusion: Persistent symptoms are associated with QOL reductions in LACC survivors. Organ-related symptoms showed smaller differences than general symptoms such as fatigue and pain. In addition to optimizing treatment to minimize organ-related morbidity, effort should be directed towards a more comprehensive and targeted morbidity management.
KW - Clinical trial
KW - Locally advanced cervical cancer
KW - Morbidity
KW - Patient reported outcome
KW - Quality of life
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150847612&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36720348
U2 - 10.1016/j.radonc.2023.109501
DO - 10.1016/j.radonc.2023.109501
M3 - Article
C2 - 36720348
SN - 0167-8140
VL - 181
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 109501
ER -